JR14a

Research use only, not for human use.

JR14a is a potent antagonist of human complement C3a receptor.

JR14a is a potent antagonist of human complement C3a receptor.

——

Animal Model:Male Wister rats (8 weeks, 250-300 g) were injected with BR103Dosage:10 mg/kg Administration:P.o. 2 h prior to agonist challenge Result:Inhibited C3aR-mediated inflammation.Animal Model:Male Wister rats (8 weeks, 250-300 g)Dosage:1 mg/kg for i.v.; 10 mg/kg for oral (Pharmacokinetic Analysis) Administration:Intravenous administration and oral administration Result:I.v.: t1/2=191 min, clearance=4.4 mL/min/kg, AUC=3795 ng?h/mL.P.o.: Cmax=88 ng/mL, Tmax=300 min, AUC=478 ng?h/mL.

5-(Bis(4-chlorophenyl)methyl)-3-methylthiophene-2-carbonyl)-l-arginine hydrochloride

Others

Other Targets

C3a

——

——

2411440-41-8

533.47

C25H26Cl2N4O3S

>98% (HPLC)

DMSO : 90 mg/mL?(168.71 mM;?Need ultrasonic)

Cc1c(C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)sc(C(c(cc2)ccc2Cl)c(cc2)ccc2Cl)c1

——

(-20℃)

With Ice Pack

≥ 2 years